Sage Journals: Discover world-class research

Abstract

Summary

What is this summary about?

Sparsentan (FILSPARI^®) is a once-daily pill for people with Immunoglobulin A (IgA) nephropathy who are at high risk for worsening kidney disease. Early results from a research study (clinical trial) called PROTECT showed that after 9 months of treatment, sparsentan lowered proteinuria more than irbesartan, a blood pressure medication commonly used to treat IgA nephropathy. These results contributed to sparsentan receiving approval in the United States, the European Union, Switzerland, and the United Kingdom in 2024.

This is a plain language summary of publication of an original article published in The Lancet (a medical journal) in November 2023, which reported further results from the PROTECT study. The original article reported on how well sparsentan worked to lower proteinuria and slow the worsening of kidney function (measured by estimated glomerular filtration rate (eGFR)) in people with IgA nephropathy compared with the highest possible dose of irbesartan over an approximately 2-year treatment period. The article also described the side effects that people enrolled in this study had with either sparsentan or irbesartan.

Keywords

eGFR kidney function PROTECT

Click here to view the PDF

Supplemental Material

sj-zip-1-trd-10.1177_26330040251355613 – Supplemental material for Sparsentan in IgA nephropathy: a plain language summary of publication for the PROTECT study

Supplemental material, sj-zip-1-trd-10.1177_26330040251355613 for Sparsentan in IgA nephropathy: a plain language summary of publication for the PROTECT study by Brad H. Rovin, Radko Komers, Chris Scroggins and Jonathan Barratt in Therapeutic Advances in Rare Disease

Footnotes

Acknowledgements

This plain language summary was written by some of the authors of the original article. The authors thank all the patients, families, and researchers who made this study possible and persevered even during the COVID-19 pandemic. Medical writing assistance and editorial support for this plain language summary were provided by Lise Barnard, PhD, Ruth E. Brown, PhD, and Lisa Havran, PhD, CMPP, of Nucleus Global, an Inizio company, in accordance with Good Publication Practice 2022 guidelines, and were funded by Travere Therapeutics, Inc. This plain language summary included a patient author and was reviewed by the Travere Therapeutics, Inc. patient advocacy team and members of the Rare Disease Patient Advisory Council (RDPAC).

Declarations

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB